ebola
viru
diseas
evd
caus
ebola
virus
result
death
accord
recent
report
mortal
rate
nowaday
one
deadli
infecti
diseas
howev
food
drug
administrationapprov
ebola
drug
vaccin
avail
yet
mainstay
therapi
support
care
high
fatal
rate
absenc
effect
treatment
vaccin
make
ebola
viru
categorya
biothreat
pathogen
fortun
seri
investig
countermeasur
develop
control
prevent
global
threat
review
summar
recent
therapeut
advanc
ongo
research
progress
research
develop
clinic
trial
develop
smallmolecul
antivir
drug
smallinterfer
rna
molecul
phosphorodiamid
morpholino
oligom
fulllength
monoclon
antibodi
vaccin
moreov
difficulti
highlight
search
effect
countermeasur
evd
addit
focu
interplay
avail
silico
predict
method
evidenc
potenti
antivir
drug
discoveri
evd
outbreak
first
may
mayjun
equateur
provinc
drc
outbreak
second
august
augustpres
kivu
provinc
drc
outbreak
first
outbreak
result
evd
case
confirm
probabl
death
overal
casefat
ratio
juli
declar
end
outbreak
latter
ongo
includ
case
confirm
probabl
death
result
casefat
rate
octob
preclin
effort
toward
specif
ebov
countermeasur
endur
year
first
treatment
vaccin
clinic
trial
conduct
ebov
outbreak
westafrica
drc
outbreak
countermeasur
evalu
westafrica
evd
outbreak
demonstr
clinic
efficaci
addit
small
number
studi
case
report
exist
experi
countermeasur
endur
mental
use
antiebola
antivir
vaccin
lead
ebov
vaccin
develop
alreadi
cover
previous
publish
review
brief
recent
updat
includ
develop
replicationcompet
rvsvzebov
rvsv
use
mayjun
equateur
drc
outbreak
ring
vaccin
trial
phase
iii
prove
well
toler
improv
efficaci
safeti
current
rvsv
investig
along
investig
therapeut
ongo
kivu
drc
outbreak
phase
ii
second
updat
includ
primeboost
vaccin
evidenc
safe
well
toler
rvsv
primeboost
vaccin
evalu
phase
ii
iii
clinic
trial
nonrepl
vaccin
virusvectorbas
evidenc
highli
effect
nonhuman
primat
nhp
current
studi
focus
therapeut
advanc
toward
evd
challeng
encount
identif
suitabl
biolog
drug
target
primari
step
toward
therapeut
develop
valid
combin
genet
biochem
structur
comput
strategi
varieti
drug
target
identifi
host
pathogen
encas
lipid
envelop
filovirus
filament
shape
linear
nonseg
negativesens
singlestrand
rna
encod
genom
contain
genet
inform
seven
structur
protein
consid
potenti
drug
target
name
transcript
activ
polymeras
cofactor
matrix
protein
nucleoprotein
np
glycoprotein
gp
rnadepend
rna
polymeras
l
structur
function
protein
aid
deciph
molecular
mechan
filoviru
lifecycl
explanatorili
review
seri
three
review
martin
et
al
describ
aspect
filoviru
entri
replic
cycl
assembl
bud
briefli
gp
heterodimer
complex
gp
surfac
protein
orchestr
viral
entri
host
cell
particip
viru
egress
due
major
role
gp
viral
entri
numer
approach
target
entri
process
explor
block
ebov
replic
earli
stage
name
immunebas
therapi
peptidebas
antivir
molecul
broad
rang
small
molecul
review
rhein
mauri
specif
entri
inhibitor
target
fusion
event
character
gp
niemannpick
interact
entri
macropinocytosi
replic
transcript
cycl
involv
releas
viral
nucleocapsid
host
cell
cytoplasm
result
synthesi
new
viral
protein
genom
whole
process
assembl
bud
coordin
np
enhanc
gp
np
bind
viral
rna
creat
rnp
complex
polymeras
l
viral
protein
np
play
import
role
rnabind
activ
multifunct
protein
suppress
hostinn
immun
found
involv
transcriptionrepl
process
togeth
nucleocapsid
assembl
interact
protein
ie
npnp
essenti
regul
format
ebov
replic
complex
effici
transcriptionrepl
block
nucleocapsid
format
proteinprotein
interact
inhibitor
lead
potenti
inhibit
ebov
exampl
peptid
first
identifi
np
ligand
specif
bind
np
block
np
oligomer
caus
releas
rna
nprna
complex
studi
identifi
acid
licochalconea
potenti
disrupt
associ
nprna
complex
aptam
pyrrolidinon
compound
recent
enethiazolidinedion
groupcontain
compound
specif
lead
specif
interact
function
nucleocapsid
matur
factor
transcriptionrepl
modul
addit
identifi
target
proteinprotein
interact
inhibitor
name
macrocycl
peptid
inhibitor
karyopherin
specif
disrupt
interact
matrix
protein
coordin
toward
viral
assembl
bud
regul
viral
transcript
structuralfunct
featur
recent
advanc
crucial
regulatori
protein
essenti
viral
messeng
rna
mrna
synthesi
genom
replic
critic
review
therefor
constitut
key
target
design
ebovspecif
drug
key
strategi
recogn
combat
ebov
includ
directli
target
viru
ii
modul
host
factor
immun
respons
iii
diseas
manag
critic
target
viral
lifecycl
among
popular
strategi
ebov
therapeut
done
either
target
initi
bind
andor
entri
viru
host
cell
later
viral
replic
packag
ebov
antivir
compound
mainli
encompass
small
molecul
antisens
therapi
immunotherapeut
drug
current
treatment
evd
center
upon
modul
coagul
maintain
oxygen
level
ebola
patient
therapeut
intervent
susten
recoveri
report
howev
signific
improv
might
observ
result
adequ
level
support
care
date
commerci
vaccin
specif
therapi
avail
ebov
howev
variou
studi
report
explain
comprehens
develop
vaccin
smallmolecul
inhibitor
repurpos
food
drug
administr
fda
approv
drug
ebola
tabl
provid
overview
antiebov
compound
level
efficaci
report
either
ic
ec
vitro
assay
ebov
clinic
statu
observ
studi
end
westafrica
ebov
outbreak
clearli
indic
protect
rhesu
monkey
follow
lethal
ebov
challeng
improv
highli
potent
vitro
efficaci
mayinga
makona
strain
compar
favipiravir
moreov
recent
administ
first
time
newborn
babi
test
broadspectrum
inhibit
variou
virus
includ
arenavirus
bunyavirus
coronavirus
paramyxovirus
flavivirus
addit
anim
surviv
efficaci
account
mice
rhesu
monkey
use
increas
dose
favipiravir
remain
potenti
antiebov
candid
westafrica
outbreak
report
surviv
rate
ebovinfect
mice
even
lowest
oral
dose
mg
kg
daili
comparison
nhp
result
surviv
rate
among
variou
fda
screen
multipl
compound
includ
amodiaquin
diphenylpyralin
ketotifen
diphenoxyl
report
inhibit
ebov
replic
other
includ
verapamil
dronedaron
sertralin
toremifen
chloroquin
teicoplanin
amiodaron
consid
ebov
entri
inhibitor
recent
tiloron
ec
report
potent
smallmolecul
inhibitor
singledaili
dose
mgkg
intraperiton
prove
efficaci
protect
mice
lethal
ebov
challeng
inhibitor
shown
figur
studi
includ
identif
coumarinbas
antihistaminelik
molecul
identifi
protect
combin
zmapp
introduc
combin
three
ebovgp
mab
demonstr
protect
rhesu
monkey
function
mechan
bind
zmapp
describ
neutral
activ
target
gp
base
glycan
cap
studi
report
optim
zmapp
nhp
use
two
chimer
mab
design
protect
ebov
makona
strain
infect
rhesu
monkey
recent
adenoassoci
virusmedi
mab
deliv
protect
mouseadapt
ebov
infect
wherea
neutral
mab
reveal
protect
also
coformul
cocktail
three
human
cocktail
ratio
current
evalu
prove
safe
well
toler
observ
immunogen
random
firstinhuman
phase
clinic
trial
therapeut
includ
nucleic
acidbas
inhibitor
phosphorodiamid
morpholino
oligom
pmo
smallinterfer
rna
sirna
involv
promot
degrad
mrna
transcript
constitut
two
essenti
class
antisens
therapi
compound
target
vital
protein
involv
ebov
transcriptiontransl
process
viral
polymeras
l
develop
underli
modif
pmo
sirna
elabor
recent
review
silico
method
drug
discoveri
hold
great
potenti
may
prove
benefici
stage
preclin
develop
drug
candid
especi
area
like
target
valid
design
compound
librari
protein
model
play
signific
role
drug
discoveri
process
goal
homolog
model
structur
predict
known
sequenc
accuraci
compar
experiment
resolv
structur
restrict
link
techniqu
presenc
insert
loop
sequenc
accur
predict
absenc
threedimension
crystal
structur
gap
known
protein
sequenc
identifi
protein
structur
significantli
grow
given
enorm
amount
data
vast
array
dna
sequenc
mirza
et
al
techniqu
avail
experiment
structur
identif
techniqu
requir
attent
comput
techniqu
activ
exploit
pharmaceut
industri
predict
protein
model
expand
scope
comput
method
improv
model
accuraci
effort
made
continu
approach
help
predict
tertiari
structur
protein
amino
acid
sequenc
combat
issu
depend
avail
inform
method
character
either
de
novo
homolog
model
templatebas
model
also
refer
homolog
model
compar
model
trust
method
model
design
similar
fold
properti
member
protein
famili
core
structur
unaffect
modif
sequenc
fundament
criteria
govern
homolog
model
contrari
predict
experi
demonstr
lower
activ
bind
potenti
compound
therefor
negat
predict
made
later
silico
refin
compound
use
md
reveal
interrupt
key
stepwis
drug
discoveri
process
target
identif
hittolead
optim
clinic
trial
along
progress
develop
smallmolecul
inhibitor
ebov
admet
absorpt
distribut
metabol
excret
toxic
ht
high
throughput
screen
pdb
protein
data
bank
pk
pharmacokinet
qsar
quantit
structureact
relationship
r
research
develop
sar
structureact
relationship
interact
sulphonamid
ligand
receptor
due
addit
water
molecul
migrat
water
molecul
outsid
explain
reduc
activ
compound
test
experiment
anoth
studi
caval
et
al
md
simul
use
platform
discern
sever
differ
dock
complex
propidium
human
acetylcholinesteras
stabl
structur
identifi
correl
experiment
verifi
bind
mode
interestingli
md
simul
assist
discoveri
develop
antivir
drug
hittolead
optim
essenti
phase
close
examin
chemic
scaffold
concern
absorpt
distribut
metabol
excret
adm
challeng
drug
discoveri
process
silico
ligandprofil
benefit
boost
repurpos
drug
notion
design
drug
control
select
profil
approach
aim
util
phenotyp
screen
hit
predict
potenti
target
mechan
action
ii
identifi
offtarget
potenti
respons
advers
reaction
side
effect
iii
care
analysi
admet
absorpt
distribut
metabol
excret
toxic
paramet
propos
potenti
hit
anoth
use
silico
method
particularli
benefici
lead
optim
quantit
structureproperti
relationship
qspr
model
use
identif
key
structur
featur
respons
interact
target
protein
mani
adm
endpoint
measur
pharmaceut
industri
qspr
model
prospect
shown
abil
extract
knowledg
wide
varieti
chemic
scaffold
prove
util
predict
model
qspr
model
base
machin
learn
techniqu
desir
achiev
optim
potenc
adm
properti
reduc
risk
failur
trial
use
qsarqspr
model
necessari
accur
predict
activ
compound
drug
discoveri
project
howev
model
provid
adequ
inform
modif
made
test
compound
next
cycl
drug
design
address
issu
match
molecular
pair
analysi
techniqu
anoth
promis
approach
method
assess
mean
effect
differ
substitu
variou
adm
paramet
permeabl
ii
solubl
iii
clearanc
iv
cytochrom
inhibit
design
new
scaffold
interact
desir
pharmacolog
target
benefit
base
find
molecular
substitut
close
link
molecular
properti
guid
design
scaffold
sever
studi
report
use
quantit
structureact
relationship
model
lead
optim
comput
drug
discoveri
proven
acceler
challeng
process
design
optim
new
drug
candid
hierarch
virtual
screen
ligandbas
structurebas
method
delin
valid
find
potenti
hit
even
earli
phase
drug
discoveri
increas
effici
ebola
hittolead
optim
interplay
sever
stage
silico
drug
design
depict
figur
rapid
develop
faster
architectur
comprehens
algorithm
highlevel
comput
impact
comput
structurebas
drug
design
antivir
drug
discoveri
lead
optim
profound
impact
futur
year
hit
identif
also
elucid
biolog
target
provid
inform
use
drug
discoveri
research
perspect
perilla
et
al
develop
show
abil
reach
millisecond
timescal
repres
interest
biolog
process
effort
made
quantum
comput
offer
excit
outlook
date
actual
quantum
comput
still
initi
stage
develop
quantum
comput
oper
execut
experiment
small
number
quantum
bit
timewis
develop
might
becom
possibl
simul
larg
biolog
system
determin
comput
fold
protein
start
amino
acid
sequenc
drug
discoveri
process
applic
promis
especi
target
identif
interact
analysi
success
rate
drug
discoveri
pipelin
involv
target
identif
screen
hittolead
optim
preclin
candid
select
within
rang
advanc
understand
mechan
mode
action
ebov
futur
silico
work
essenti
role
develop
drug
candid
devast
evd
muhammad
usman
mirza
http
michiel
vanmeert
http
amjad
ali
http
